Background: A pulmonary hypertensive crisis (PHC) can be a life-threatening condition. We established a PHC model by exposing rats with monocrotaline (MCT)-induced pulmonary hypertension to acute hypoxia, and investigated the effects of vasopressin, phenylephrine, and norepinephrine on the PHC. Methods: Four weeks after MCT 60 mg kg À1 administration i.v., right ventricular systolic pressure (RVSP), systolic BP
Editor's key points
There is no treatment guideline for the diagnosis and treatment of a pulmonary hypertensive crisis (PHC) in pulmonary hypertension. In a rat model for pulmonary hypertension, the authors compared vasopressin, norepinephrine, and phenylephrine in the treatment of PHC induced by acute hypoxia. Vasopressin was the most beneficial in improving systemic haemodynamics, cardiac function, and survival during a PHC in this rat model.
In patients with pulmonary hypertension (PH) from congenital heart diseases, a pulmonary hypertensive crisis (PHC) is a lifethreatening situation characterised by a sudden increase in pulmonary vascular resistance, right heart failure, and systemic hypotension during the perioperative period of cardiovascular surgeries. 1 This crisis also can occur in idiopathic pulmonary arterial hypertension, sarcoidosis, pulmonary fibrosis during cardiac 2 and non-cardiac surgeries, 3, 4 and lung transplantation. 5, 6 Management of the crisis is challenging, because there is no treatment guideline or expert consensus specifying concrete agents as standard medication and diagnostic criteria for PHC. 1, 7, 8 In addition, no animal model of PHC has been reported to investigate PHC management to date, despite the availability of various models of PH. 9, 10 Thus, there are few comparative data on the agents for PHC treatment either clinically or experimentally. At present, vasopressors/inotropes including norepinephrine and phenylephrine have been used as rescue therapy 11 to raise the systemic BP above the pulmonary arterial pressure to maintain coronary perfusion, 1, 5, 11 even though the level of evidence for this therapy was shown to be low in a systematic review 12 and in guidelines. 7 Recently, vasopressin has been used in the management of PHC in cardiac 11, 13, 14 and in noncardiac surgery. 2 Vasopressin has a constrictive effect on the systemic vasculature 15e19 and a vasodilatory effect on the pulmonary artery via endothelial nitric oxide synthase (eNOS). 15e17 Nonetheless, endothelial function of the pulmonary artery has been impaired, and the effects of vasopressin on pulmonary artery pressure have not been consistent in PH patients 12, 20 and in animal models. 9, 19 The vasodilatory effect of vasopressin on the pulmonary arteries may also be uncertain in PH, 17, 21 and data justifying the use of vasopressin for PHC remain limited. 12, 22 We aimed to develop an experimental model of PHC by creating monocrotaline (MCT)-induced PH in rats 10, 23 which were subsequently exposed to acute hypoxia. Then, we examined whether vasopressin, norepinephrine, and phenylephrine could improve haemodynamics, cardiac motion, oxygenation, and survival period during PHC using the developed PHC model. We also measured isometric tension of pulmonary and femoral arteries to investigate the underlying modifying mechanism of these agents.
Methods
Inflammation and endothelial cell injury in whole pulmonary arteries are involved in the genesis of PHC, 1, 24 and acute hypoxia is an important trigger inducing PHC. 24 We reproduced PHC by MCT-induced PH in rats which were subsequently exposed to acute hypoxia. 10 
Monocrotaline-induced pulmonary hypertension in rats
Eight-week-old male Sprague-Dawley rats (Japan SLC, Shizuoka, Japan) were divided into the PH group (n¼182), which received MCT 60 mg kg À1 s.c., and the control group (n¼90), which received saline. 23 Rats were housed up to three per cage and had free access to water and food with constantly maintained room temperature and humidity under a 12e12 h lightedark cycle (light phase 7:00e19:00). For some experiments, PH rats were further divided into the vasopressin, norepinephrine, phenylephrine, and saline treatment groups. Animals were euthanised with an i.v. or i.p. injection of pentobarbital sodium (120 mg kg À1 ) at the end of the experiment or to remove pulmonary and femoral artery rings.
Haemodynamic measurements
Four weeks after each injection, we measured systolic blood pressure (SBP), mean BP (MBP), right ventricular systolic pressure (RVSP) as an indicator of pulmonary artery pressure 23, 25 and cardiac output (CO), as described previously. 23 SBP, MBP, and RVSP were examined simultaneously through catheters in the femoral artery and right ventricle, respectively (PowerLab system, ADInstruments, Colorado Springs, CO, USA) under positive pressure ventilation with sevoflurane 4 vol% at a fraction of inspiratory oxygen (FiO 2 ) of 1.0 (SN-480-7 ventilator, Shinano, Tokyo, Japan). CO was measured twice at each measurement by the thermodilution technique. Cardiac index (CI) was calculated as the ratio of CO to body weight. 23, 26 Pulmonary vascular resistance index (PVRI) was defined as RVSP divided by CI. 23, 26 The left femoral vein was cannulated with a catheter to administer drugs. Local anaesthesia was achieved with lidocaine 0.5% during every surgical procedure. Adequate pain relief was ensured by confirming a lack of pedal withdrawal response and righting reflex to pain stimuli before and during the surgical procedures. The absence of increases in HR and MBP during the surgical procedures was also confirmed.
Echocardiographic studies
Two-dimensional echocardiography was performed using a Sonos 5500 (Hewlett-Packard, Andover, MA, USA). The right ventricular inner area (RVA) and left ventricular inner area (LVA) in diastole were measured in the short-axis view at the level of the papillary muscles. Right ventricular dilatation was evaluated by the ratio of RVA to LVA (RVA/LVA) in a blinded manner. Cardiac septal motion was examined in the same view. Assessment of oxygenation P a O 2 was measured in the PH rats. Arterial blood (0.4 ml) was drawn through the femoral artery catheter and was analysed at three time points (1.2 ml withdrawn in total): before, during PHC, and after administration of the agents at maximum dose (ABL800Flex blood gas analyser; Radiometer, Brønshøj, Denmark).
Induction of a pulmonary hypertensive crisis

Survival
We examined the survival rate at 120 min after the induction of PHC in the PH rats with administration of the agents.
Isometric tension in pulmonary and femoral arteries
Four weeks after MCT or saline injection, we prepared ring samples from pulmonary and femoral arteries in rats for measurements of isometric tension as described previously. 27, 28 The ring samples were pre-contracted with norepinephrine 100 nM. The concentration-response curves to vasopressin and acetylcholine for relaxation of the pulmonary artery rings from control and PH rats were constructed. Some samples from control rats were pre-treated with the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine monomethyl ester (L-NAME) 30 mM 20 min before contraction with norepinephrine. The relaxation is expressed as a percentage of the norepinephrine-induced contraction.
Pulmonary and femoral artery rings from control and PH rats were contracted with KCl 65 mM and washed. To construct the concentration response curves for contraction, the ring samples were exposed to increasing concentrations of vasopressin and phenylephrine. The results are expressed as a percentage of the KCl-induced contraction. Preliminarily, we confirmed histological changes such as increased medial wall thickness and muscularisation of the pulmonary arteries in the MCT-induced PH rats (data not shown).
Data analysis
All values are shown as mean (standard error). CI and HR were analysed using one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test. MBP and isometric tension data were analysed with two-way ANOVA followed by the Tukey-Kramer post hoc test. The log-rank test was used to assess the significance of the Kaplan-Meier analysis of survival in the PHC model. Statistical significance was set at P<0.05. All statistical analyses were performed with Prism 6 version 6.04 (GraphPad Prism 6, La Jolla, CA, USA).
Results
Monocrotaline-induced pulmonary hypertension
RVSP in the PH group was significantly higher than that in the control group [ 
Haemodynamic and echocardiographic evaluation
After changing FiO 2 from 1.0 to 0.1, SBP was significantly decreased compared with the basal level, whereas RVSP was increased slightly and became equal to or exceeded the SBP (n¼12; Fig. 1a and b). The ventilation at FiO 2 0.1 also significantly decreased CI and increased PVRI ( Fig. 1c and d ). After returning FiO 2 from 0.1 to 1.0, SBP, CI, and PVRI also returned to basal levels ( Fig. 1bed ). On echocardiography, the RVA/LVA was significantly increased in the PH rats compared with control rats (Fig. 1e , f, and h). After PHC induction, the ratio was further increased ( Fig. 1g and h) (n¼12 in control and n¼12 in PHC rats). Moreover, interventricular septal flattening and paradoxical motion were also observed in PHC (Video 2). The times to obtain the PHC state from starting FiO 2 0.1 until the return to basal levels at FiO 2 1.0 were 6.4 (2.2) and 6.0 (1.6) min, respectively. The induction of PHC and return to basal levels appeared to cause a similar change in each animal. Therefore, we considered that MCT-induced PH with acute hypoxia at FiO 2 0.1 could reproduce acute right heart failure mimicking the PHC state. Supplementary data related to this article can be found online at https://doi.org/10.1016/j.bja.2019.01.014
Effects of vasopressin, phenylephrine, and norepinephrine on haemodynamic parameters
We measured the haemodynamic changes in response to i.v. administration of vasopressin, norepinephrine, and phenylephrine during PHC. We determined maximum doses of vasopressin, phenylephrine, and norepinephrine to be 1.5 mg ( Fig. 2a) . Vasopressin 1.5 mg kg À1 h À1 also significantly increased CI compared with that before administration ( Fig. 2d ) and significantly decreased PVRI (Fig. 2g) . In contrast, administration of phenylephrine 2 mg kg À1 h À1 during PHC significantly increased not only MBP, but also RVSP more than those before administration while not significantly improving CI (Fig. 2b, Effects of vasopressin, phenylephrine, and norepinephrine on cardiac motion
We examined the effects of vasopressin, phenylephrine, and norepinephrine by echocardiography in control rats (n¼18) and in PH rats with PHC (n¼6 each with vasopressin, phenylephrine, and norepinephrine). RVA/LVA in PHC was significantly increased compared with the basal value (Fig. 3a, b , and f) and was significantly reversed with vasopressin 1.5 mg kg À1 h À1 (Fig. 3c and f) significantly decreased P a O 2 [3.1 (0.3) kPa, P<0.05] compared with that before each treatment. We could not measure P a O 2 in the norepinephrine group because of the fragile haemodynamics as mentioned above.
Effects of vasopressin, phenylephrine, and norepinephrine on survival
With vasopressin 1.5 mg kg À1 h À1 administration (n¼6), five rats survived through the entire observational period of 120 min in PHC (Fig. 4) . With saline (n¼6), only 40% of the rats survived at 120 min. With the phenylephrine 2 mg kg À1 h À1 (n¼6) and norepinephrine 12 mg kg À1 h À1 (n¼6) treatments, all rats died before 120 min. A Kaplan-Meyer analysis of survival rate in PHC showed that vasopressin significantly improved the survival rate compared with saline, phenylephrine, and norepinephrine. Phenylephrine and norepinephrine worsened the survival rate compared even with saline.
Effects of vasopressin, norepinephrine, and phenylephrine on haemodynamic parameters in control rats exposed to acute hypoxia
We examined haemodynamic changes in response to the i.v. administration of vasopressin, phenylephrine, and norepinephrine in control rats exposed to acute hypoxia (n¼6 for each drug). After changing the FiO 2 from 1.0 to 0.1, MBP decreased significantly compared with the basal levels, whereas RVSP did not change significantly ( Supplementary  Fig. S1 ). The times to obtain a constant state of SBP and RVSP with hypoxia in the vasopressin, phenylephrine, and norepinephrine groups were 7.0 (2.6), 7. 
Relaxation effect of vasopressin and acetylcholine on isometric tension of pulmonary artery rings
Vasopressin produced concentration-dependent relaxations of pulmonary artery ring samples from control rats whose rings had been contracted with norepinephrine 100 nM (n¼4) (Fig. 5a ). The relaxation was greatly inhibited by pre-treatment with L-NAME 30 mM (n¼4). However, vasopressin did not cause relaxation of pulmonary artery rings from PH rats (n¼4). Acetylcholine also produced concentration-dependent relaxations of pulmonary artery ring samples from control rats (n¼10). The relaxation was impaired in pulmonary artery rings from PH rats (n¼10) (Fig. 5b ).
Constrictive effect of vasopressin and phenylephrine on isometric tension of pulmonary and femoral artery rings
Vasopressin produced dose-dependent contraction of the femoral artery but not pulmonary artery ring samples in PH rats (Fig. 5c ) (n¼8 in vasopressin, n¼6 in phenylephrine). In contrast, phenylephrine caused dose-dependent contraction of both pulmonary and femoral artery ring samples ( The administration rate of each agent was fixed at 2 ml h À1 . *P<0.05 compared with saline (log-rank test).
Discussion
Report a novel rat model of PHC created by exposing rats with MCT-induced PH to acute hypoxia. Induction of the PHC showed a critically decreased SBP equal to or exceeded by RVSP, increased PVRI, and decreased CI. This model also showed exacerbated right ventricle dilatation, interventricular septal flattening, and paradoxical septal motion, indicating aggravation of right heart failure. Induction of PHC reproducibly showed similar haemodynamic changes with a similar time course in all 30 PH rats. Therefore, this model appeared to reproduce the haemodynamics and cardiac motion of PHC at least in a certain situation. Returning FiO 2 to 1.0 also recovered all haemodynamic parameters, and thereby we consider that this model could be reversible and endurable enough to examine PHC management as a PHC model. We also showed that vasopressin returned the haemodynamic parameters and cardiac motion to basal values in the PH rats and improved oxygenation and the survival period in PHC, whereas norepinephrine and phenylephrine worsened them in this PHC model. 12 right heart failure from PH may affect the sensitivity to norepinephrine. Combined treatments with pulmonary vasodilators might be a more appropriate way to use norepinephrine practically. In the control group, acute hypoxia with FiO 2 0.1 induced similar effects on haemodynamics to those in the PH rats, although to a lesser degree. It is probable that control rats may be more tolerant to hypoxia than PH rats. Acute hypoxia slightly, but not significantly, increased PVRI in the control rats. Sevoflurane has been reported to have a vasodilatory effect 31 and to reduce hypoxic pulmonary vasoconstriction 31, 32 in a dose-dependent manner via a variety of mechanisms. 33e35 Therefore, in this study, although the precise mechanism for the absence of an increase in PVRI is obscure, it is possible that sevoflurane 4% could affect this lack of increase. As with the PHC rats, vasopressin also significantly recovered the decreased MBP and increased CI in the control rats with hypoxia. Hypoxia-induced decrease in MBP and the vasopressin-and phenylephrineinduced increases in MBP did not affect HR in the PH and control rats. These results suggested impaired baroreflex control of HR. Because sevoflurane is known to reduce baroreflex in a dose-dependent manner, 35e37 sevoflurane 4% might have affected the reflex in the present study. Vasopressin improved P a O 2 in PHC. These results are consistent with previous reports showing improved oxygenation in PH in infants with congenital heart disease 38, 39 and in adults undergoing cardiac surgery. 13 Vasopressin also improved oxygenation more than epinephrine did in a postresuscitation model, because of a lower ventilation-perfusion mismatch. 40 In the present study, an increased CI with vasopressin and subsequent increase in pulmonary blood flow at least could contribute to the increases in oxygen delivery and in P a O 2 . This increased P a O 2 also could improve cardiac motion and the duration of survival in PHC. In contrast, the decreased P a O 2 with phenylephrine in PHC may be a result of a decrease in CI. Taken together, these results suggest that vasopressin may be useful in the management of PHC at least in this situation.
In isometric tension measurements, vasopressin showed a selective vasoconstrictive effect on the femoral artery, but not the pulmonary artery rings from PH rats. These results are consistent with previous reports in humans 15 and chronic hypoxia-induced PH rats. 19 The selective constrictive effect appeared to be consistent with an increase in MBP, but not RVSP with vasopressin in PHC, which increased the pressure gradient between them. In contrast, phenylephrine constricted both the pulmonary and femoral artery rings. Therefore, it may be reasonable that phenylephrine increased both MBP and RVSP with little increase in the pressure gradient. In this study, although vasopressin decreased PVRI in PHC, the relaxation effect of vasopressin on the pulmonary artery rings from MCT-induced PH rats was significantly reduced compared with that from the control rats. The relaxation effect in control rats was also inhibited by pre-treatment with L-NAME. Vasodilation of the pulmonary artery with vasopressin has been reported to be through the eNOS/NO pathway. 16, 17, 41 However, various studies of PH using MCT-induced rats 42 reported impaired activity of eNOS, decreased eNOS expression, 43, 44 eNOS activity, 42, 45 NO product, 45, 46 cyclic guanosine monophosphate content, 47 and endothelium-dependent relaxation 46, 48 in pulmonary artery. These data may be consistent with our results of impaired relaxation of pulmonary artery with vasopressin in PH. In contrast, Resta and colleagues 49 reported a modest increase of eNOS expression and augmented vasodilation with vasopressin in isolated lung from MCT-induced PH rats. As Nakazawa and colleagues 46 noted, the discrepancy between these results in MCT-induced PH rats might be because of the difference in the preparations used such as pulmonary artery rings and isolated lungs. Although the mechanism of the decrease in PVRI with vasopressin remains to be elucidated, a selective increase in MBP, but not RVSP, and a decrease in PVRI with vasopressin might contribute to improvements of CI, P a O 2 , and survival rate.
In addition, vasopressin 1.5 mg kg À1 h À1 increased MBP in both PHC and PH similarly, whereas phenylephrine 2 mg kg The vasoconstrictive effect of vasopressin was preserved in hypoxia, acidosis, 50, 51 catecholamine-refractory septic shock, 52 and cardiopulmonary resuscitation compared with catecholamine. 6, 11, 44 These findings also support the use of vasopressin in the management of PHC.
Interestingly, in the PH rats without PHC, although vasopressin 1.5 mg kg À1 h À1 significantly increased MBP, it decreased CI to below its basal levels. These results are consistent with previous reports that vasopressin decreases CI and RVSP while increasing SBP in rats under normal 18 and chronic hypoxic conditions, 19 and in canines with acute PH. 9 Our study and these previous studies were performed under states of maintained circulation, and the SBP was higher than the pulmonary arterial pressure (PAP). Collectively, a beneficial effect of vasopressin on CI appeared to be exerted more in a collapsed than maintained circulation. These assumptions may be supported by the findings that vasopressin improved refractory severe hypotension in non-cardiac 53 and cardiac surgeries 14 and in septic shock. 52 Although an MCT-induced PH model has been used to assess the effects of drugs in clinical settings, 54 this model is now known to have some limitations when translated to human PH. Because it lacks the complete pathological changes of severe and chronic PH in humans such as plexiform lesions, this model may represent acute/subacute damage of curable PH. 10 Inflammation and vasoactivity have also been thought to be important mechanistic components of this PH model. 55 However, PHC can arise from various types of PH at various levels of severity.
1e6 PHC is heterogeneous and complex, and although the factors that promote PHC are not completely understood, inflammation, endothelial dysfunction, and pulmonary artery contractility may be important. 1, 11, 24, 56 Indeed in the perioperative period of congenital heart diseases with cardiopulmonary bypass, these factors have been associated with PHC. 1, 56 In such cases, PH stage can be acute or subacute and curable because surgery must be performed before the onset of high PVR and irreversible pathological changes. 57 Therefore, it seems possible that MCT-induced PH could be applied for PHC experiments on these terms. Similarly, hypoxia could also be an important trigger of PHC, but various other stimuli can also be triggers. 8 Thus, it might be possible that our PHC model in this study could represent acute right heart failure mimicking PHC at least in a certain situation. However, the development of various PHC states, using other known PH than MCT-induced models, may provide better understanding. Although we examined single treatment with vasopressor, other inotropes and pulmonary vasodilators such as dobutamine and prostacyclin analogue 1, 7 have been applied for rescue of PHC. 11 Investigation of combined treatments using a PHC model may provide more appropriate management of PHC.
In conclusion, we reproduced an experimental model of PHC for the first time, to our knowledge, which showed that vasopressin, but not norepinephrine and phenylephrine, might be useful for PHC management. These results could justify future studies of PHC management focussing on vasopressin.
